Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Experimental Medicine for COVID-19
2020-002230-32Phase 2Unknown
- Sponsor
- University of Edinburgh
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of GB0139 and Nafabelltan in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Edinburgh. Primary endpoint: Safety outcomes. Status: unknown.
02
Drugs
GB0139Nafabelltan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002230-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002230-32.